Literature DB >> 10063991

Incidence of venous thromboembolism in families with inherited thrombophilia.

P Simioni1, B J Sanson, P Prandoni, D Tormene, P W Friederich, B Girolami, S Gavasso, M V Huisman, H R Büller, J Wouter ten Cate, A Girolami, M H Prins.   

Abstract

The risk of spontaneous or risk-period related venous thromboembolism in family members of symptomatic carriers of antithrombin (AT), protein C (PC) or protein S (PS) defects, as well as of the Factor V Leiden mutation is still undefined. We performed a retrospective cohort study in family members (n = 793) of unselected patients with a documented venous thromboembolism and one of these deficiencies to make an estimate of this risk. The annual incidences of total and spontaneous venous thromboembolic events in carriers of AT, PC or PS defects (n = 181) were 1.01% and 0.40%, respectively, as compared to 0.10% and 0.04% in non-carriers, respectively (relative risks both 10.6). In carriers of Factor V Leiden (n = 224), the annual incidences of total and spontaneous venous thromboembolism were 0.28% and 0.11%, respectively, as compared to 0.09% and 0.04% in non-carriers, respectively (relative risks 2.8 and 2.5). Additional risk factors (immobilisation, surgery and trauma: oral contraceptive use; and pregnancy/ post-partum) increased the risk of thrombosis in carriers of AT, PC and PS defects as compared to non-carriers (relative risks 8.3, 6.4 and 8.2, respectively). Oral contraceptive use and pregnancy/ post-partum period increased the risk of thrombosis in carriers of Factor V Leiden to 3.3-fold and 4.2-fold, respectively, whereas other risk factors had only a minor effect. These data lend some support to the practice of screening family members of symptomatic carriers of a AT, PC and PS deficiency. For family members of symptomatic carriers of Factor V Leiden, screening does not seem to be justified except for women in fertile age.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10063991

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  35 in total

1.  Thrombophilia testing: what do we think the tests mean and what should we do with the results?

Authors:  T Baglin
Journal:  J Clin Pathol       Date:  2000-03       Impact factor: 3.411

2.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Factor V Leiden in Chioggia: a prevalence study in patients with venous thrombosis, their blood relatives and the general population.

Authors:  Gianluca Gessoni; Sara Valverde; Rosa Canistro; Fabio Manoni
Journal:  Blood Transfus       Date:  2010-07       Impact factor: 3.443

Review 4.  Risk factors for venous and arterial thrombosis.

Authors:  Emanuele Previtali; Paolo Bucciarelli; Serena M Passamonti; Ida Martinelli
Journal:  Blood Transfus       Date:  2010-10-25       Impact factor: 3.443

Review 5.  Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients.

Authors:  Ana T Rocha; Edison F Paiva; Arnaldo Lichtenstein; Rodolfo Milani; Cyrillo Filho Cavalheiro; Francisco H Maffei
Journal:  Vasc Health Risk Manag       Date:  2007

6.  Stroke or left atrial thrombus prediction using antithrombin III and mean platelet volume in patients with nonvalvular atrial fibrillation.

Authors:  Seo-Won Choi; Bo-Bae Kim; Dong-Hyun Choi; Geon Park; Byung Chul Shin; Heesang Song; DongHun Kim; Dong-Min Kim
Journal:  Clin Cardiol       Date:  2017-08-14       Impact factor: 2.882

7.  Testing for thrombophilia: clinical update.

Authors:  Neil Graham; Hunaid Rashiq; Beverley J Hunt
Journal:  Br J Gen Pract       Date:  2014-02       Impact factor: 5.386

8.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy.

Authors:  Shannon M Bates; Anita Rajasekhar; Saskia Middeldorp; Claire McLintock; Marc A Rodger; Andra H James; Sara R Vazquez; Ian A Greer; John J Riva; Meha Bhatt; Nicole Schwab; Danielle Barrett; Andrea LaHaye; Bram Rochwerg
Journal:  Blood Adv       Date:  2018-11-27

9.  Venous thromboembolism in pregnancy.

Authors:  Marcelo P Villa-Forte Gomes
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-04

10.  A pilot study to assess the feasibility of a multicenter cluster randomized trial for the management of asymptomatic persons with a thrombophilia.

Authors:  Philip S Wells; Martha L Louzada; Monica Taljaard; David R Anderson; Susan R Kahn; Nicole J Langlois; Julie Rutberg; Michael J Kovacs; Marc A Rodger
Journal:  J Genet Couns       Date:  2009-06-03       Impact factor: 2.537

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.